id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-P-7034-0007,FDA,FDA-2017-P-7034,Response Letter from FDA CDER to Jubilant Generics Limited,Other,Letter(s),2025-07-31T04:00:00Z,2025,7,2025-07-31T04:00:00Z,,2025-07-31T18:24:31Z,,0,0,09000064b8ebc5b5